Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm
Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.
In this interview, Matthew D. Galsky, MD, discusses how the FDA approval of perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility is reshaping the treatment landscape and raising new questions about the future role of surgery and response-guided approaches. Galsky is a medical oncologist at the Icahn School of Medicine at Mount Sinai and the deputy director of the Mount Sinai Tisch Cancer Center in New York, New York.